News

BioSpace16h
Sarepta Fallout Continues with EU’s Negative Opinion of Elevidys in Ambulatory Patients
The European Union’s health regulatory agency did not endorse approving Elevidys for ambulatory patients with Duchenne ...
Investor's Business Daily on MSN16h
Sarepta Therapeutics' Brutal Week Continues With Bad News Out Of Europe
Sarepta Therapeutics' brutal week continued Friday after European officials rejected the company's controversial gene therapy ...
Elevidys Halt Sparks Analyst Downgrades—Sarepta Races To Revise Label
Analysts downgraded Sarepta as FDA pause on Elevidys raises regulatory uncertainty, leading to significant stock pressure and ...
BioSpace8d
Sarepta Up 18% After Business Overhaul as Analysts Cautiously Optimistic
Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...
STAT4dOpinion
The crisis over Sarepta’s Duchenne therapy is a mess. But the lesson is clear
The crisis over Sarepta Therapeutics' Duchenne therapy offers a valuable lesson: Listening to critics, and responding with ...
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sarepta Therapeutics (SRPT), Illumina (ILMN) and Alpha Teknova (TKNO)
Detailed price information for Alpha Teknova Inc (TKNO-Q) from The Globe and Mail including charting and trades.